Replies to post #6335 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Dasgrunt, they already have patent protection for HSDD until 2028 and general testosterone replacement therapy until 2031. It is the CV and Breast Cancer event reduction patents they are working on now.

If the argument I submitted to Dentons last summer which pointed out the examiner's misinterpretation of an article used to justify the rejection of the CV event reduction patent claims has any merit, they should have an strong chance of getting the CV related patent claim allowed.

[Just the facts maam]

Dasgrunt, they already have patent protection for HSDD until 2028 and general testosterone replacement therapy until 2031. It is the CV and Breast Cancer event reduction patents they are working on now.

If the argument I submitted to Dentons last summer which pointed out the examiner's misinterpretation of an article used to justify the rejection of the CV event reduction patent claims has any merit, they should have an strong chance of getting the CV related patent claim allowed.